These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19690193)

  • 1. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.
    Mom CH; Verweij J; Oldenhuis CN; Gietema JA; Fox NL; Miceli R; Eskens FA; Loos WJ; de Vries EG; Sleijfer S
    Clin Cancer Res; 2009 Sep; 15(17):5584-90. PubMed ID: 19690193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
    Leong S; Cohen RB; Gustafson DL; Langer CJ; Camidge DR; Padavic K; Gore L; Smith M; Chow LQ; von Mehren M; O'Bryant C; Hariharan S; Diab S; Fox NL; Miceli R; Eckhardt SG
    J Clin Oncol; 2009 Sep; 27(26):4413-21. PubMed ID: 19652058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.
    Hotte SJ; Hirte HW; Chen EX; Siu LL; Le LH; Corey A; Iacobucci A; MacLean M; Lo L; Fox NL; Oza AM
    Clin Cancer Res; 2008 Jun; 14(11):3450-5. PubMed ID: 18519776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
    Tolcher AW; Mita M; Meropol NJ; von Mehren M; Patnaik A; Padavic K; Hill M; Mays T; McCoy T; Fox NL; Halpern W; Corey A; Cohen RB
    J Clin Oncol; 2007 Apr; 25(11):1390-5. PubMed ID: 17416859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.
    Trarbach T; Moehler M; Heinemann V; Köhne CH; Przyborek M; Schulz C; Sneller V; Gallant G; Kanzler S
    Br J Cancer; 2010 Feb; 102(3):506-12. PubMed ID: 20068564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
    Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
    Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
    Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
    Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
    Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
    Adjei AA; Croghan GA; Erlichman C; Marks RS; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Bruzek LM; Atherton P; Thibault A; Palmer PA; Kaufmann SH
    Clin Cancer Res; 2003 Jul; 9(7):2520-6. PubMed ID: 12855626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
    Rosen LS; Puzanov I; Friberg G; Chan E; Hwang YC; Deng H; Gilbert J; Mahalingam D; McCaffery I; Michael SA; Mita AC; Mita MM; Mulay M; Shubhakar P; Zhu M; Sarantopoulos J
    Clin Cancer Res; 2012 Jun; 18(12):3414-27. PubMed ID: 22510349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
    Rajan A; Carter CA; Kelly RJ; Gutierrez M; Kummar S; Szabo E; Yancey MA; Ji J; Mannargudi B; Woo S; Spencer S; Figg WD; Giaccone G
    Clin Cancer Res; 2012 Apr; 18(8):2344-51. PubMed ID: 22371451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
    Okusaka T; Ikeda M; Fukutomi A; Kobayashi Y; Shibayama K; Takubo T; Gansert J
    Jpn J Clin Oncol; 2014 May; 44(5):442-7. PubMed ID: 24782485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study.
    Stemmler HJ; Kahlert S; Brudler O; Beha M; Müller S; Stauch B; Heinemann V
    Clin Oncol (R Coll Radiol); 2005 Dec; 17(8):630-5. PubMed ID: 16372489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.
    Giaccone G; González-Larriba JL; van Oosterom AT; Alfonso R; Smit EF; Martens M; Peters GJ; van der Vijgh WJ; Smith R; Averbuch S; Fandi A
    Ann Oncol; 2004 May; 15(5):831-8. PubMed ID: 15111354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
    Leijen S; van Geel RM; Pavlick AC; Tibes R; Rosen L; Razak AR; Lam R; Demuth T; Rose S; Lee MA; Freshwater T; Shumway S; Liang LW; Oza AM; Schellens JH; Shapiro GI
    J Clin Oncol; 2016 Dec; 34(36):4371-4380. PubMed ID: 27601554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Rizvi NA; Hellmann MD; Brahmer JR; Juergens RA; Borghaei H; Gettinger S; Chow LQ; Gerber DE; Laurie SA; Goldman JW; Shepherd FA; Chen AC; Shen Y; Nathan FE; Harbison CT; Antonia S
    J Clin Oncol; 2016 Sep; 34(25):2969-79. PubMed ID: 27354481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
    Belyanskaya LL; Marti TM; Hopkins-Donaldson S; Kurtz S; Felley-Bosco E; Stahel RA
    Mol Cancer; 2007 Oct; 6():66. PubMed ID: 17953743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
    Richter S; Bedard PL; Chen EX; Clarke BA; Tran B; Hotte SJ; Stathis A; Hirte HW; Razak AR; Reedijk M; Chen Z; Cohen B; Zhang WJ; Wang L; Ivy SP; Moore MJ; Oza AM; Siu LL; McWhirter E
    Invest New Drugs; 2014 Apr; 32(2):243-9. PubMed ID: 23645447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
    Siegel-Lakhai WS; Crul M; Zhang S; Sparidans RW; Pluim D; Howes A; Solanki B; Beijnen JH; Schellens JH
    Br J Cancer; 2005 Nov; 93(11):1222-9. PubMed ID: 16251868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.